All Posts By

Smartkarma Daily Briefs

Daily Brief Equity Bottom-Up: China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine
  • Novatek (3034.TT): Re-Qualify IPhone OLED Display DDIC; the Downturn Might Be Ending Soon.


China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine

By Xinyao (Criss) Wang

  • Weight loss and Alzheimer’s disease (AD) have been ranked among the top indications in the pharmaceutical history and are undeniable opportunities, but they are expected to generate different investment returns.
  • We have noticed that some companies have started developing GLP-1 gene therapy. We would be cautious about this.
  • Without strong fundamentals but is eager to go public on A-share market, AIM Vaccine (6660 HK) seems more enthusiastic about capital operations to make quick money.We consider this company risky.

Novatek (3034.TT): Re-Qualify IPhone OLED Display DDIC; the Downturn Might Be Ending Soon.

By Patrick Liao


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Kurita Water Industries, Shinko Electric Industries, TSE Tokyo Price Index TOPIX and more

By | Daily Briefs, Japan

In today’s briefing:

  • Index Rebalance & ETF Flow Recap: NKY, ASX, Liontown, J&T Express, JP/IN Positioning, IndusInd Bank
  • Last Week In Event SPACE: Shinko Electric Industries, MGM China, Decente, Sankei Real Estate,
  • Challenge Is to Simultaneously Reduce Cash on Hand and Achieve Profitability over Cost of Capital


Index Rebalance & ETF Flow Recap: NKY, ASX, Liontown, J&T Express, JP/IN Positioning, IndusInd Bank

By Brian Freitas


Last Week In Event SPACE: Shinko Electric Industries, MGM China, Decente, Sankei Real Estate,

By David Blennerhassett


Challenge Is to Simultaneously Reduce Cash on Hand and Achieve Profitability over Cost of Capital

By Aki Matsumoto

  • Managers self-analyze the factors that lead to P/B of below 1x, as companies fail to appreciate their growth potential and to ensure profitability in excess of their cost of capital.
  • This seems to be dilemma in that companies’ failure to realize sufficient profitability, along with insufficient growth investments, prevents them from sharing the image of corporate value growth with investors.
  • Managers believe that the first step is to improve ROE by reshuffling business portfolios and promoting profitability improvement, but reducing excess cash and increasing shareholder returns should be pursued simultaneously.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: AIM Vaccine, Alibaba Group Holding , Vinda International and more

By | China, Daily Briefs

In today’s briefing:

  • China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine
  • ECM Weekly (22nd Oct 2023) – J&T, Cuscal, Liontown, Cainiao, ZJLD, Taiwan Cement, Zomato, Hana Micro
  • (Mostly) Asia-Pac Weekly Risk Arb Wrap: Lithium Power, Vinda, Origin Energy, Liontown, Kenedix REITs


China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine

By Xinyao (Criss) Wang

  • Weight loss and Alzheimer’s disease (AD) have been ranked among the top indications in the pharmaceutical history and are undeniable opportunities, but they are expected to generate different investment returns.
  • We have noticed that some companies have started developing GLP-1 gene therapy. We would be cautious about this.
  • Without strong fundamentals but is eager to go public on A-share market, AIM Vaccine (6660 HK) seems more enthusiastic about capital operations to make quick money.We consider this company risky.

ECM Weekly (22nd Oct 2023) – J&T, Cuscal, Liontown, Cainiao, ZJLD, Taiwan Cement, Zomato, Hana Micro

By Clarence Chu

  • Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
  • J&T Global Express (1519 HK) launched its US$500m HK IPO earlier in the week, with more than half of the Offer Shares going to its pre-IPO shareholders.
  • It was a busy week for placements as well, with Liontown Resources (LTR AU)‘s stealing the spotlight with its equity/debt raising, after Albemarle withdrew its acquisition bid. 

(Mostly) Asia-Pac Weekly Risk Arb Wrap: Lithium Power, Vinda, Origin Energy, Liontown, Kenedix REITs

By David Blennerhassett


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Bharat Electronics, Cheng Shin Rubber Ind Co., Ltd., Li Auto , Astra International, China Unicom Hong Kong, Wuhan Jingce Electronic Group, Japan Post Bank, Liontown Resources, Giordano International, Kurita Water Industries and more

By | Daily Briefs, Most Read

In today’s briefing:

  • NIFTY50 Index Rebalance Preview: Two’s Company; Three’s A Crowd
  • Index Rebalance & ETF Flow Recap: Taiwan Div+, Nifty50, Cainiao IPO, Delta Electronics
  • HSTECH Index Rebalance Preview: Round-Trip Trade of US$556m in December
  • WisdomTree Emerging Markets High Dividend Index Rebalance: Huge Turnover & Trade Next Week
  • HSCEI Index Rebalance Preview: One Change; Capping Impact Increases
  • ChiNext/​​​ChiNext50 Index Rebalance Preview: Sector Rotation Continues
  • Index Rebalance & ETF Flow Recap: HSCEI, HSTECH, TOPIX FFW, SSE50, AS51, ChiNext, Kenedix, Liontown
  • Liontown Resources (LTR AU): State of Play
  • Asian Dividend Gems: Giordano International
  • Index Rebalance & ETF Flow Recap: NKY, ASX, Liontown, J&T Express, JP/IN Positioning, IndusInd Bank


NIFTY50 Index Rebalance Preview: Two’s Company; Three’s A Crowd

By Brian Freitas

  • There should be two changes for the NIFTY Index (NIFTY INDEX) in March. That could increase to three, but that would take some big price moves from now to January.
  • Impact on the potential changes is pretty large at over 6 days of ADV to trade from passive trackers. The impact is over 11 days of delivery volume.
  • Inclusion of Avenue Supermarts Ltd (DMART IN) in the F&O segment before January could lead to another change.

Index Rebalance & ETF Flow Recap: Taiwan Div+, Nifty50, Cainiao IPO, Delta Electronics

By Brian Freitas


HSTECH Index Rebalance Preview: Round-Trip Trade of US$556m in December

By Brian Freitas

  • With no stocks in inclusion or deletion zone, we do not expect any constituent changes for the Hang Seng TECH Index (HSTECH INDEX) in December.
  • Capping changes will result in a one-way turnover of 2.16% and that will result in a round-trip trade of US$556m.
  • The impact of capping changes has doubled over the last month and there will be more changes from now till the official capping is done on 28 November.

WisdomTree Emerging Markets High Dividend Index Rebalance: Huge Turnover & Trade Next Week

By Brian Freitas

  • The WisdomTree Emerging Markets High Dividend Index is a fundamentally weighted index that measures the performance of high dividend yield stocks within emerging markets.
  • The October rebalance will result in a one-way turnover of ~37% and in a one-way trade of US$926m. There are 92 stocks with over 1 day of ADV to trade.
  • In Asia, the largest buy flows are expected on Astra International (ASII IJ) and the largest sell flows on POSCO Holdings (005490 KS)

HSCEI Index Rebalance Preview: One Change; Capping Impact Increases

By Brian Freitas


ChiNext/​​​ChiNext50 Index Rebalance Preview: Sector Rotation Continues

By Brian Freitas

  • Nearing the end of the review period, we forecast 8 changes for the ChiNext Index (SZ399006 INDEX) and 5 changes for the ChiNext 50 Index in December.
  • Given stock selection uses liquidity as a major input, the impact of passive trading will be much larger on the deletions as compared to the additions.
  • The potential adds have outperformed the potential deletes, but relative performance has been drifting lower over the last few months. There are stocks that will have flows from other indices.

Index Rebalance & ETF Flow Recap: HSCEI, HSTECH, TOPIX FFW, SSE50, AS51, ChiNext, Kenedix, Liontown

By Brian Freitas


Liontown Resources (LTR AU): State of Play

By Brian Freitas

  • Liontown Resources (LTR AU) resumes trading today after announcing a raise of up to A$1.18bn to fully fund the Kathleen Valley Lithium Project to first production and beyond.
  • The equity component is up to A$421m and the placement price of A$1.8/share is a 35.5% discount to the last close.
  • The placement price is higher than the stock price prior to the Albemarle Corp (ALB US) offer and during a period when its peers have performed poorly.

Asian Dividend Gems: Giordano International

By Douglas Kim

  • Giordano, one of the most recognizable apparel business in Asia, has been improving its operations materially with solid growth in sales and profits. 
  • Giordano provides very high dividend yield and payout. The consensus expects DPS of HKD 0.28 for Giordano in 2023, which would suggest a dividend yield of 12.8%. 
  • We like the company’s high dividend yield, loyal customer base, and attractive valuations. It is trading at EV/EBITDA of 3.6x and P/B of 1.5x. 

Index Rebalance & ETF Flow Recap: NKY, ASX, Liontown, J&T Express, JP/IN Positioning, IndusInd Bank

By Brian Freitas


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: ASML Holding NV, Iridium Communications and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • ASML’s Gloomy Outlook Sinks Semis
  • IRDM: Valuation Reset, Cash Flow Rising


ASML’s Gloomy Outlook Sinks Semis

By William Keating

  • ASML reported Q323 revenues of €6.7 billion, largely in line with guidance, down 3% QoQ but up 15.5% YoY. Q423 revenue forecast of €6.9 billion. 
  • ASML remains on track for a remarkable 30% YoY growth in 2023 revenues
  • ASML forecasting 2024 as a zero growth year as order intake in Q323 falls to €2.6 billion, massively down on the €8.9 billion in the year-ago quarter. 

IRDM: Valuation Reset, Cash Flow Rising

By Hamed Khorsand

  • IRDM used its third quarter results as means to update investors on where operating EBITDA would end up for 2023 and the continued progress with direct to device
  • IRDM reported quarterly results missing our estimates due to a larger than expected decline in equipment revenue. 
  • The Qualcomm (QCOM) partnership is poised to emerge as the most significant catalyst for 2024

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Blue Jet Healthcare Ltd, Basilea Pharmaceutica Ag and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Blue Jet Healthcare IPO: Niche Offering and Long-Standing Customer Relationship Are Key Positives
  • Basilea Pharmaceutica – Antifungal addition to bolster pipeline


Blue Jet Healthcare IPO: Niche Offering and Long-Standing Customer Relationship Are Key Positives

By Tina Banerjee

  • Blue Jet Healthcare Ltd (BJHC IN) is a CDMO focusing on specialty pharmaceutical and healthcare ingredients and intermediates. The company targets to raise $100M from its upcoming India IPO.
  • The IPO, which will open for subscription on October 25, consists of OFS of 24.3M shares by two of the promoters. The price range has been fixed at INR329–346/share.
  • Blue Jet enjoys a competitive advantage in the global contrast media market through established customer relationships with the top contrast media manufacturers. The company is on a capacity expansion spree.

Basilea Pharmaceutica – Antifungal addition to bolster pipeline

By Edison Investment Research

Basilea has announced an expansion of its portfolio to foster long-term growth, a key strategic priority for management, leveraging expertise in the commercialisation of its two key anti-infective products, Cresemba and Zevtera. The company will in-license GR-2397, a clinical-stage antifungal compound targeting invasive mould infections, mainly caused by the Aspergillus species. The Phase II-ready asset has Qualified Infectious Disease Product, Orphan Drug and Fast Track designations from the US FDA for invasive aspergillosis, which often leads to priority review post a New Drug Application (NDA) filing and grants 10 years of US market exclusivity. Basilea will make an upfront payment of $2m, followed by ~$69m in milestones and tiered royalties. Our valuation of Basilea remains unchanged, and will be reassessed once additional information becomes available.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Gol Linhas Aereas – Pref and more

By | Daily Briefs, Industrials

In today’s briefing:

  • GOL – ESG Report – Lucror Analytics


GOL – ESG Report – Lucror Analytics

By Charles Macgregor

Lucror Analytics’ ESG Scores are based on a 3-tiered scale and are adjusted for Controversies (if applicable).
We assess GOL’s ESG as “Adequate”, in line with its Environment, Social and Governance scores. Controversies are “Immaterial” and Disclosure is “Adequate”.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Gol Linhas Aereas – Pref and more

By | Daily Briefs, Industrials

In today’s briefing:

  • GOL – ESG Report – Lucror Analytics


GOL – ESG Report – Lucror Analytics

By Charles Macgregor

Lucror Analytics’ ESG Scores are based on a 3-tiered scale and are adjusted for Controversies (if applicable).
We assess GOL’s ESG as “Adequate”, in line with its Environment, Social and Governance scores. Controversies are “Immaterial” and Disclosure is “Adequate”.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Aareal Bank AG, Bank Central Asia, New World Development, ASX Ltd, The Diverse Income Trust PLC and more

By | Daily Briefs, Financials

In today’s briefing:

  • Advent & CenterBridge/​Aareal Bank AG: Delisting Offer
  • Bank Central Asia (BBCA IJ) – Batting Above Average
  • NWD 17 HK: FY23 Results Update, to Reset and Transform, and a Beta Play if Rate Expectation Peaks
  • ASX – New Listings Big Decline, SG&A Costs Up Substantially, Best Income Delta Is Non-Core
  • Diverse Income Trust (The) – Managers see relative upside in any environment


Advent & CenterBridge/​Aareal Bank AG: Delisting Offer

By Jesus Rodriguez Aguilar

  • The Delisting Agreement should end the Atlantic bidding for Aareal Bank AG (ARL GR) saga. Atlantic has been hoovering shares in the market since last 7 June.
  • Atlantic probably owns c.90.8%. Based on daily trading volumes, it would take many days to acquire shares and reach the 95% barrier required to implement a squeeze-out.
  • Spread is 0.3%/2.3% (gross/annualised, assuming settlement on 8 December), not too bad for a quick buck, but liquidity is razor thin.

Bank Central Asia (BBCA IJ) – Batting Above Average

By Angus Mackintosh

  • Bank Central Asia (BBCA IJ) released another set of positive numbers in 3Q2023, outperforming the overall sector on loan and CASA growth, allowing the banks to maintain NIMs and profitability.
  • The bank’s digital banking franchise continues to grow, with 31 million users of its mobile banking, boosting transactions and customer numbers, with a broadening of features and service offerings available. 
  • Consumer banking, SME, and Corporate lending will continue to drive loan growth and credit costs continue to come down boosting profits. Bank Central Asia remains a core holding. 

NWD 17 HK: FY23 Results Update, to Reset and Transform, and a Beta Play if Rate Expectation Peaks

By Jacob Cheng

  • In this insight, we summarized NWD’s FY2023 results.  We think the gearing and balance sheet, the biggest concern that market has, has been clearly addressed
  • NWD has announced disposal of its stake in NWS, and will have more corporate actions to come.  The dividend expectation is reset
  • We view most of the negatives are priced in at current valuation.  NWD is much better than a Chinese developer, and should not be trading at 0.19x PB

ASX – New Listings Big Decline, SG&A Costs Up Substantially, Best Income Delta Is Non-Core

By Daniel Tabbush

  • ASX Ltd (ASX AU) is seeing weakness across key revenue items with best delta in what is non- core, net interest income. Suddenly, its operating cash flow is negative.
  • New listings are down from 217 companies to 57 companies YoY to FY23 and their market capitalization is down from AUD59bn to AUD3bn YoY to FY23.
  • SG&A costs seem to be rising structurally now at 28% of gross profit in FY23 compared with 23% in FY22 and compared with 17-19% in preceding years.

Diverse Income Trust (The) – Managers see relative upside in any environment

By Edison Investment Research

Since launch in 2011, the Diverse Income Trust (DIVI) has grown its dividend every year (compounding at an average annual rate of 6.5%), including during the global pandemic, when many UK dividends were cut. The strength of the trust’s revenue growth is also reflected in its capital appreciation that has enabled DIVI to deliver robust total returns. As globalisation has fractured over the last three years, equity income strategies have become increasingly popular with global investors, and the UK top 100 index (in US dollar terms) has outperformed other developed market indices. DIVI’s two co-managers, Gervais Williams and Martin Turner, are very optimistic because they believe that UK large-cap stocks will continue to outperform and historically UK small-caps have outpaced the performance of their larger peers. In this scenario, the prospects for the trust’s multi-cap approach look very favourable.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Vinda International, WH Group, Giordano International, Nameson Holdings, OPAP SA, WD-40 Company and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Vinda (3331 HK): Tanoto Sees The Wood
  • WH Group (288 HK):  Potential US Listing Of Smithfield Foods Could Be A Catalyst
  • Asian Dividend Gems: Giordano International
  • Weekly Wrap – 20 Oct 2023
  • OPAP – Strategy delivering incremental growth
  • WDFC: Price Increase Premium Going Away


Vinda (3331 HK): Tanoto Sees The Wood

By David Blennerhassett

  • On the 27 April, Vinda (3331 HK) announced its controlling shareholder Essity (ESSITYB SS) would commence a strategic review of its 51.59% ownership. See Essity Mulls Holding In Vinda (3331 HK).
  • That shook a variety of suitors out of the woodwork (so to speak) including (reportedly) Brazil’s Suzano, the world’s largest hardwood pulp producer, Bain Capital, CVC Capital, and DCP Capital.
  • The latest (alleged) interested party is the Tanoto family, currently holding a 7.03% stake, having first cleared 5% on the 26 September. 

WH Group (288 HK):  Potential US Listing Of Smithfield Foods Could Be A Catalyst

By Steve Zhou, CFA

  • According to public news yesterday, WH Group (288 HK) plans to list its US pork business Smithfield Foods, the largest US pork producer, back in the US again. 
  • WH Group currently trades at 5x 2024E PE, assuming earnings return to the 2022 level in 2024E.  Since 2016, the company has had an average PE of 11x. 
  • The stock is a buy with a fairly strong catalyst in the potential US listing of the Smithfield Foods business, while downside is limited. 

Asian Dividend Gems: Giordano International

By Douglas Kim

  • Giordano, one of the most recognizable apparel business in Asia, has been improving its operations materially with solid growth in sales and profits. 
  • Giordano provides very high dividend yield and payout. The consensus expects DPS of HKD 0.28 for Giordano in 2023, which would suggest a dividend yield of 12.8%. 
  • We like the company’s high dividend yield, loyal customer base, and attractive valuations. It is trading at EV/EBITDA of 3.6x and P/B of 1.5x. 

Weekly Wrap – 20 Oct 2023

By Charles Macgregor

Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.

In this Insight:

  1. Medco Energi
  2. NagaCorp Ltd
  3. China Vanke
  4. Lippo Malls Indonesia Retail Trust
  5. Tata Motors Ltd

and more…


OPAP – Strategy delivering incremental growth

By Edison Investment Research

OPAP’s management is successfully executing its strategy of growing the core brands and customer interactions online and offline, as evidenced by increasing online exposure and revitalising growth in its mature retail core activities, while maintaining its leading corporate and social responsibility (CSR) credentials. Its exclusive licences in the majority of its activities enable high levels of profitability, cash generation and shareholder returns. We see attractive upside to our DCF-based valuation of €17.9/share, with the added appeal of a prospective dividend yield of 10.7%.


WDFC: Price Increase Premium Going Away

By Hamed Khorsand

  • Previous price increases by WD-40 Company (WDFC) led to the Company reporting a year over year increase in quarterly revenue, but with those prices increases being lapped in fiscal 2024
  • WDFC was able to reduce its inventory level in the quarter, but unit volume growth remains elusive. Higher operating expenses are expected to prevent earnings growth in fiscal 2024
  • WDFC reported fiscal fourth quarter sales of $140.5 million compared to $141.7 million achieved in fiscal third quarter.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars